Relafen review

Relafen can be generically prescribed as nabumetone and is commonly used in the treatment of pain and inflammation caused by arthritis. Relafen is part of the family of medications known as NSAIDs, or nonsteroidal anti-inflammatory drugs.

Relafen is not appropriate for all patients and a thorough medical evaluation is strongly suggested before prescribing Relafen to any patient. Patients with a medical history which includes heart disease, heart attack, blood clots, stroke, congestive heart failure, high blood pressure, kidney disease, liver disease, asthma, stomach ulcers, stomach bleeding, cigarette smoking, nasal polyps, bleeding disorders, or blood clotting disorders.

The American Food and Drug Administration gave Relafen a pregnancy risk category C. Relafen has been proven to cause harm or birth defects in an unborn baby. Relafen has also been proven to pass through the mother’s breast milk and cause harm to a nursing baby. Women who are pregnant, could become pregnant or are nursing should not take Relafen.

Side effects are common however can be severe. Severe side effects require medical attention without delay. Side effects requiring urgent medical attention may include severe tingling, bruising, muscle weakness, pain, numbness, sore throat, fever, headache accompanied by a severe skin rash that blisters or peels, nausea and stomach pain accompanied by low fever, loss of appetite, dark urine, pale stools, and jaundice, coughing up blood or vomit that resembles coffee grounds, stools that are black, bloody, or tarry, swelling, rapid weight gain, edema, a decrease in urination or not being able to produce urine at all, chest pain, shortness of breath, weakness with slurred speech, or difficulty maintaining balance, coordination, or the ability to properly see.

Most side effects are not as significant, although they have the potential to be bothersome. Patients should report the side effects that they experience to the prescribing physician. Most patients report side effects such as ringing in the ears, blurry vision, nausea or upset stomach, bloating, mild skin rash, itching, gas, mild heartburn, dizziness, nervousness, headaches, stomach pain, constipation, or diarrhea.

Relafen should be taken as it has been prescribed without alteration by the patient. Should the patient miss a scheduled dose of Relafen, the dose should be taken when remembered unless it is almost time for the next dose of Relafen. In this case the missed dose should be skipped entirely and the dosing schedule resumed at the following dose. Patients should never take a double dose of Relafen to make up for a missed dose or for any other reason as this can result in an accidental overdose. In the event that an overdose is suspected the patient should receive prompt medical attention. An overdose is likely to present with symptoms which include drowsiness, stomach pain, nausea, vomiting, coughing up blood, black or bloody stools, fainting, shallow breathing, coma, or death.

Other medications may interact with Relafen which may cause adverse effects. Patients are urged to inquire with either the prescribing physician or the pharmacist before taking any type of new medication, which includes over the counter medications, herbal remedies, prescription medications, and vitamin or energy supplements. Medications with a known history of negative drug interactions include but are not limited to ACE inhibitors, steroids, diuretics, additional NSAID medications, blood thinners, methotrexate, and lithium.

Patients should be encouraged to avoid alcoholic beverages as this elevates the risk of stomach bleeding. Patients should also be warned that Relafen increases the sensitivity to sunlight which may result in severe sun burns if appropriate precautions are ignored. Patients should be vigilant not to purchase or use over the counter medications without checking with a pharmacist or physician as numerous products on the market contain aspirin or additional NSAIDs. This may lead to an overdose or other complications.

Relafen has the following structural formula:

Chemical structure of relafen

• Molecular formula of relafen is C15H16O2
• Chemical IUPAC Name is 4-(6-methoxynaphthalen-2-yl)butan-2-one
• Molecular weight is 228.286 g/mol
Relafen available : 750mg tablets

Generic name: Nabumetone

Brand name(s): Arthaxan, Balmox, Consolan, Dolsinal, Flambate, Listran, Mebutan, Nabumetona, Nabumetonum, Nabuser, Prodac, Relif, Relifen, Relifex, Unimetone

  Your Relafen review